{"id":26831,"date":"2023-12-27T22:56:31","date_gmt":"2023-12-28T03:56:31","guid":{"rendered":"https:\/\/www.investorsradar.com\/?p=26831"},"modified":"2023-12-29T01:53:41","modified_gmt":"2023-12-29T06:53:41","slug":"apple-to-appeal-after-us-backs-ban-on-watch-imports","status":"publish","type":"post","link":"http:\/\/www.investorsradar.com\/apple-to-appeal-after-us-backs-ban-on-watch-imports\/","title":{"rendered":"Apple to appeal after US backs ban on watch imports"},"content":{"rendered":"<div>\n<h2 class=\"\" data-sourcepos=\"1:1-1:84\">Masimo&#8217;s Pulse Oximeter Patents Ground Apple Watch Series 9 and Ultra 2 in the US<\/h2>\n<p data-sourcepos=\"3:1-3:1\">A legal tug-of-war over pulse oximetry technology has left Apple&#8217;s latest smartwatches grounded in the US. Masimo, a medical tech company, claims Apple&#8217;s Apple Watch Series 9 and Ultra 2 infringe on its patents for light-based blood oxygen measurements in wearables. This resulted in a US International Trade Commission (ITC) ruling banning these watches from import, a decision upheld by the Biden administration.<\/p>\n<p data-sourcepos=\"5:1-5:10\">Frustrated by the import ban, Apple has launched an appeal and filed an emergency request to pause the ban while it tweaks its watches to potentially bypass Masimo&#8217;s patents. Until a resolution is reached, the latest smartwatches are unavailable for new purchases in the US, barring existing retail stock or third-party resellers like Amazon.<\/p>\n<p data-sourcepos=\"7:1-7:83\">The dispute stems from Masimo&#8217;s patents (numbers 10,912,502 and 10,945,648) and its assertion that Apple&#8217;s pulse oximetry tech in the Series 6 onwards (launched in 2020) infringes upon them. This issue previously led to a legal battle with a hung jury but no clear victor.<\/p>\n<p data-sourcepos=\"9:1-9:371\">Masimo, with its $2 billion annual revenue, finds itself facing the tech giant Apple, boasting a $400 billion revenue and the dominant smartwatch market share with 230 million units sold since 2015. Despite the size difference, Masimo has managed to land a significant blow with its patent claims, causing a temporary but impactful disruption for Apple&#8217;s smartwatch line.<\/p>\n<p data-sourcepos=\"11:1-11:43\">Here&#8217;s a quick breakdown of the key points:<\/p>\n<ul data-sourcepos=\"13:1-18:0\">\n<li data-sourcepos=\"13:1-13:112\"><strong>Masimo claims patent infringement:<\/strong>\u00a0Apple Watch&#8217;s pulse oximetry tech allegedly infringes Masimo&#8217;s patents.<\/li>\n<li data-sourcepos=\"14:1-14:122\"><strong>Import ban imposed:<\/strong>\u00a0The ITC ruling and Biden administration&#8217;s decision ban Apple Watch Series 9 and Ultra 2 imports.<\/li>\n<li data-sourcepos=\"15:1-15:134\"><strong>Apple appeals and seeks temporary pause:<\/strong>\u00a0Apple fights the ban while potentially modifying its watches to avoid the patent issue.<\/li>\n<li data-sourcepos=\"16:1-16:165\"><strong>Latest Apple Watches unavailable:<\/strong>\u00a0New Series 9 and Ultra 2 are off Apple&#8217;s US website and stores,\u00a0except for remaining retail stock or resale by third parties.<\/li>\n<li data-sourcepos=\"17:1-18:0\"><strong>Pulse oximetry market:<\/strong>\u00a0Masimo,\u00a0a smaller player,\u00a0challenges Apple&#8217;s smartwatch dominance through intellectual property claims.<\/li>\n<\/ul>\n<p data-sourcepos=\"19:1-19:261\">The outcome of this legal battle will determine the future of pulse oximetry technology in wearables and the availability of Apple&#8217;s latest smartwatches in the US market. As both sides fight for their interests, one thing is clear: the battle for a slice of the wearable health tech market just got a lot more heated.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Masimo&#8217;s Pulse Oximeter Patents Ground Apple Watch Series 9 and Ultra 2 in the US A legal tug-of-war over pulse oximetry technology has left Apple&#8217;s latest smartwatches grounded in the US. Masimo, a medical tech company, claims Apple&#8217;s Apple Watch Series 9 and Ultra 2 infringe on its patents for light-based blood oxygen measurements in [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":26842,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"slim_seo":[],"footnotes":""},"categories":[30],"tags":[1876,537,4294,7998,1074,1064],"class_list":["post-26831","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tech","tag-appeal","tag-apple","tag-backs","tag-ban","tag-imports","tag-watch"],"_links":{"self":[{"href":"http:\/\/www.investorsradar.com\/wp-json\/wp\/v2\/posts\/26831"}],"collection":[{"href":"http:\/\/www.investorsradar.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.investorsradar.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.investorsradar.com\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"http:\/\/www.investorsradar.com\/wp-json\/wp\/v2\/comments?post=26831"}],"version-history":[{"count":0,"href":"http:\/\/www.investorsradar.com\/wp-json\/wp\/v2\/posts\/26831\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.investorsradar.com\/wp-json\/wp\/v2\/media\/26842"}],"wp:attachment":[{"href":"http:\/\/www.investorsradar.com\/wp-json\/wp\/v2\/media?parent=26831"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.investorsradar.com\/wp-json\/wp\/v2\/categories?post=26831"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.investorsradar.com\/wp-json\/wp\/v2\/tags?post=26831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}